UCLA's Jonsson Comprehensive Cancer Center has over 235 physicians and scientists who have played crucial roles in the development of FDA approved cancer therapies for patients world-wide. The JCCC provides the latest in experimental cancer treatments and hundreds of clinical trials.
Scientists from UCLA's Jonsson Comprehensive Cancer Center, led by pioneering cancer researchers Drs. Dennis Slamon and Zev Wainberg, are bringing stem cell science directly to cancer patients with an exciting new clinical trial scheduled to begin in early 2014. Partially funded by the California Institute of Regenerative Medicine (CIRM), the project builds on Slamon's previous work to develop a drug that targets tumor initiating cells, that was conducted with Wainberg. In this NBC 4 news piece, Slamon and Wainberg discuss this breakthrough research, and the powerful potential this anti-cancer drug has in battling the disease.
Doctors and UCLA's Jonsson Comprehensive Cancer Center were able to save the life of Kevin Carlberg who at the age of 25 was diagnosed with glioblastoma.
UPDATE 8/31/2009: Kevin Carlberg suffered a recurrence of his cancer and, despite treatment, he passed away on Saturday, August 29, 2009. Through his participation in a clinical trial at UCLA's Jonsson Comprehensive Cancer Center, Carlberg lived about four times longer than the average glioblastoma patient. His participation also helped move cancer research forward. We thank him.
www.cancer.ucla.edu UCLA Jonsson Comprehensive Cancer Center Director, Dr. Judith C. Gasson, discusses the fact that cancer is not one disease, and different forms of cancer require different cures. That's why our researchers are developing and testing targeted therapies and more personalized approaches to fighting all cancers.
High school student and aspiring baseball player Nick Hurtado discusses his experience battling bone cancer with "CBS Sports Center." With the support of his high school league and the efforts of UCLA's Dr. Noah Federman, Hurtado is beating the odds against bone cancer.
In an exciting breakthrough, scientists at UCLA's Jonsson Comprehensive Cancer Center recently reported an encouraging increase in progression-free survival (or PFS, the length of time a patient is on treatment without tumor growth) for patients with HER2-negative breast cancer, a particularly aggressive form of the disease. In this informative video, lead researcher Dr. Richard Finn explains the positive results of this pioneering study and the possibilities it opens up for future breast cancer treatments.